CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Project Number||pCODR 10084|
|Strength||60 mg per vial|
|Indication||Multiple Myeloma (relapsed)|
|Funding Request||In combination with dexamethasone alone in the treatment of patients with relapsed multiple myeloma who have received 1 to 3 prior lines of therapy|
|Review Status||Notification to Implement Issued|
|Pre Noc Submission||Yes|
|NOC Date||November 22, 2016|
|Manufacturer||Amgen Canada Inc.|
|Sponsor||Amgen Canada Inc.|
|Submission Date||September 9, 2016|
|Submission Deemed Complete||September 16, 2016|
|Submission Type||New Indication|
|Prioritization Requested||Not Requested|
|Stakeholder Input Deadline ‡||September 23, 2016|
|Check-point meeting||November 1, 2016|
|pERC Meeting||January 19, 2017|
|Initial Recommendation Issued||February 2, 2017|
|Feedback Deadline ‡||February 16, 2017|
|pERC Reconsideration Meeting||March 16, 2017|
|Final Recommendation Issued||March 30, 2017|
|Notification to Implement Issued||April 17, 2017|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.